NCT01421017View on ClinicalTrials.gov

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2011

Primary Completion Date

July 1, 2016

Study Completion Date

August 6, 2016

Conditions

Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

Interventions

RADIATION

Radiation

DRUG

Imiquimod

DRUG

Cyclophosphamide

Trial Locations (1)

10016

New York University Medical Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

NYU Langone Health

OTHER

NCT01421017 - Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | Biotech Hunter | Biotech Hunter